Protalix BioTherapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Protalix BioTherapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.74M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $53.40M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $65.49M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $47.64M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $38.35M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $62.90M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $54.69M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $34.24M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $21.08M | Mar 12, 2020 |
| FY2017 | Dec 31, 2016 | $9.20M | Mar 6, 2018 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.01M | Mar 6, 2018 |
| FY2017 | Dec 31, 2016 | $801.0K | Mar 6, 2018 |
| FY2017 | Dec 31, 2015 | $3.63M | Mar 6, 2018 |
| FY2016 | Dec 31, 2014 | $2.89M | Mar 16, 2017 |
| FY2015 | Dec 31, 2013 | $0 | Mar 8, 2016 |
| FY2014 | Dec 31, 2012 | $26.28M | Mar 12, 2015 |
| FY2013 | Dec 31, 2011 | $1.44M | Mar 13, 2014 |
| FY2012 | Dec 31, 2010 | $6.86M | Feb 28, 2013 |
| FY2011 | Dec 31, 2009 | ($3.19M) | Feb 27, 2012 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($6.60M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $2.93M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $8.31M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | ($14.93M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($27.58M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($6.52M) | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $291.0K | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($3.56M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($7.74M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($7.26M) | Mar 12, 2020 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($5.50M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $3.92M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $10.46M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | ($13.01M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($20.46M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $2.71M | Feb 27, 2023 |
| FY2019 | Dec 31, 2019 | $2.20M | Mar 12, 2020 |
| FY2019 | Sep 30, 2019 | ($1.54M) | Mar 12, 2020 |
| FY2019 | Jun 30, 2019 | ($5.84M) | Mar 12, 2020 |
| FY2019 | Mar 31, 2019 | ($5.53M) | Mar 12, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.57M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $12.97M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $17.09M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $29.35M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $29.73M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $38.17M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $44.62M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $33.33M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $32.17M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $30.41M | Mar 18, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.68M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $12.19M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $14.96M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $11.71M | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $12.73M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $11.15M | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $9.90M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $10.92M | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $11.53M | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $9.36M | Mar 18, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.99M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $8.67M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | ($1.32M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | ($25.00M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | ($10.29M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | ($26.11M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | ($19.36M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | ($7.74M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | ($9.99M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | ($32.10M) | Mar 18, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.64M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $1.28M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $1.15M | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | $628.0K | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | $1.46M | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | $655.0K | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | $627.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $686.0K | Mar 30, 2021 |
| FY2019 | Dec 31, 2017 | $971.0K | Mar 12, 2020 |
| FY2018 | Dec 31, 2016 | $849.0K | Mar 18, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $82.35M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $73.42M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $84.43M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $55.79M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $73.67M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $67.93M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $45.39M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $61.13M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $72.21M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $82.25M | Mar 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.12M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $30.21M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $50.87M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $66.43M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $79.70M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $94.97M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $115.71M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | $114.01M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | $101.67M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | $92.20M | Mar 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $48.23M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $43.21M | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | $33.57M | Mar 18, 2026 |
| FY2025 | Dec 31, 2022 | ($10.64M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2021 | ($6.04M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2020 | ($27.04M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2019 | ($70.32M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2018 | ($52.88M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2017 | ($29.46M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2016 | ($9.96M) | Mar 12, 2020 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($385.00M) | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | ($378.39M) | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | ($381.55M) | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | ($389.86M) | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | ($374.93M) | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | ($347.35M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($340.83M) | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | ($322.55M) | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | ($296.10M) | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | ($212.66M) | Mar 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $14.68M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | $19.76M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | $23.63M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | $17.11M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | $38.99M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | $18.27M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $17.79M | Mar 30, 2021 |
| FY2020 | Dec 31, 2018 | $37.81M | Mar 30, 2021 |
| FY2020 | Dec 31, 2017 | $51.16M | Mar 30, 2021 |
| FY2019 | Dec 31, 2016 | $63.28M | Mar 12, 2020 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 31, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Mar 18, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Mar 18, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 17, 2025 |
| FY2023 | Dec 31, 2021 | 0 | Mar 14, 2024 |
| FY2022 | Dec 31, 2020 | 0 | Feb 27, 2023 |
| FY2021 | Dec 31, 2019 | (1) | Mar 31, 2022 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 80.43M | Mar 18, 2026 |
| FY2025 | Dec 31, 2024 | 75.85M | Mar 18, 2026 |
| FY2024 | Dec 31, 2023 | 72.95M | Mar 17, 2025 |
| FY2023 | Dec 31, 2022 | 53.79M | Mar 14, 2024 |
| FY2022 | Dec 31, 2021 | 45.56M | Feb 27, 2023 |
| FY2021 | Dec 31, 2020 | 34.77M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 14.84M | Mar 30, 2021 |
| FY2019 | Dec 31, 2018 | 14.84M | Mar 12, 2020 |
| FY2018 | Dec 31, 2017 | 143.73M | Mar 18, 2019 |
| FY2017 | Dec 31, 2016 | 124.13M | Mar 6, 2018 |